LGK-974 is under clinical development by Novartis and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas.

By Dr. Sanchari Sinha Dutta, Ph.D. New research uncovers how distinct molecular profiles and immune signatures in metastatic ...

Patients with lung-metastatic pancreatic ductal adenocarcinoma survive longer than those with liver metastases. A study now leverages real-world data to identify distinct molecular and immune ...

The Paul-Ehrlich-Institute (PEI) in Germany has granted approval to continue subject enrolment in cohort 5 of Oncolytics ...

Most metastatic deposits are solid and ... which implies a primary site from the colon, pancreas, or ovary (Fig. 8). Thyroid carcinoma metastases may also calcify. One of the strengths of US ...

pancreatic ductal adenocarcinoma, recurrent head and neck cancer squamous cell carcinoma, locally advanced or metastatic urothelial carcinoma, non-small cell lung cancer, esophageal squamous cell ...

Oncolytics Biotech received approval from Germany\u2019s Paul-Ehrlich-Institute to advance Cohort 5 of the GOBLET study, ...

Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the ...

Pancreatic ductal adenocarcinoma (“PDAC”) accounts ... Other less common metastatic sites are the lungs, brain, kidney, and bone. In its early stages, pancreatic cancer does not typically ...

Tumor Treating Fields therapy demonstrates increased overall survival in patients with unresectable pancreatic cancer. The ...

Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for ...